OMERS ADMINISTRATION Corp Takes Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

OMERS ADMINISTRATION Corp bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) during the 4th quarter, Holdings Channel reports. The fund bought 54,400 shares of the biotechnology company’s stock, valued at approximately $135,000.

Several other hedge funds also recently modified their holdings of ACRS. Assenagon Asset Management S.A. raised its position in shares of Aclaris Therapeutics by 113.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 211,585 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $1,003,000. JPMorgan Chase & Co. raised its position in shares of Aclaris Therapeutics by 942.0% in the 4th quarter. JPMorgan Chase & Co. now owns 88,320 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 79,844 shares during the period. Marshall Wace LLP acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $6,532,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $383,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $1.35 on Wednesday. Aclaris Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.17. The firm’s 50 day moving average price is $1.35 and its two-hundred day moving average price is $2.22. The firm has a market cap of $146.18 million, a P/E ratio of -2.60 and a beta of 0.42.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. On average, sell-side analysts anticipate that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ACRS. Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of Aclaris Therapeutics in a research report on Wednesday, May 14th. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, Scotiabank cut their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.